65540-83-2

Basic information

• Product Name: 3-(Benzoxazol-2-yl)benzyl alcohol
• Synonyms: 3-(Benzoxazol-2-yl)benzyl alcohol
• CAS NO: 65540-83-2
• Molecular Formula: C14H11NO2
• Molecular Weight: 225.2426
• Mol File: 65540-83-2.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 385.759 °C at 760 mmHg
• Flash Point: 187.1 °C
• Appearance: /
• Density: 1.261 g/cm³
• CAS DataBase Reference: 3-(Benzoxazol-2-yl)benzyl alcohol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(Benzoxazol-2-yl)benzyl alcohol(65540-83-2)
• EPA Substance Registry System: 3-(Benzoxazol-2-yl)benzyl alcohol(65540-83-2)

Safety Data

• Hazardous Substances Data: 65540-83-2(Hazardous Substances Data)

Upstream product

• 619-44-3 methyl 4-iodobenzoate 
• 273-53-0 benzoxazole 
• 20000-53-7 2-(4-methoxycarbonylphenyl)-1,3-benzoxazole 
• 615-18-9 2-chloro-1,3-benzoxazole 
• 873-75-6 4-bromobenzenemethanol 

Relevant articles and documents

CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS

Described herein are compounds and pharmaceutical compositions which inhibit N-acylethanolamine acid amidase (NAAA). Described herein are methods for synthesizing the compounds set forth herein and methods for formulating these compounds as pharmaceutical compositions which include these compounds. Also described herein are methods of inhibiting NAAA in order to sustain the levels of palmitoylethanolamide (PEA) and other N-acylethanolamines (NAE) that are substrates for NAAA, in conditions characterized by reduced concentrations of NAE. Also, described here are methods of treating and ameliorating pain, inflammation, inflammatory diseases, and other disorders in which modulation of fatty acid ethanolamides is clinically or therapeutically relevant or in which decreased levels of NAE are associated with the disorder.

ALIPHATIC AMINO BIS-ARYL SQUALENE SYNTHASE INHIBITORS

This invention relates to a class of novel aliphatic amino bis-aryl compounds containing at least four carbon atoms and an amino group either substituted thereon or incorporated therein and is further linked or bridged to two mono- and/or bicyclic rings. Compounds of this invention reduce levels of serum cholesterol in the body without significantly reducing mevalonic metabolite synthesis. This invention relates also to pharmacological compositions and method of treatment for lowering serum cholesterol levels using the compounds of this invention.